Drug manufacturers’ conditions on 340B pricing when covered entities use contract pharmacies violate federal law and ultimately diminish states’ public health efforts, 25 states told two federal appeals courts yesterday.
Drug manufacturers’ conditions on 340B pricing when covered entities use contract pharmacies violate federal law and ultimately diminish states’ public health efforts, 25 states told two federal appeals courts yesterday.
*Sign up for news summaries and alerts from 340B Report